Immune Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops therapeutic agents in the fields of immuno-inflammation, dermatology, and immuno-oncology. The company's lead product candidate is bertilimumab, a clinical-stage human antibody, which is in Phase II clinical trial that targets eotaxin-1 for the treatment of bullous pemphigoid, crohn's, and ulcerative colitis diseases. It also develops NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, which is in preclinical stage for the treatment of atopic dermatitis and psoriasis. The company's immuno-oncology pipeline includes Ceplene for the maintenance of remission in patients with acute myeloid leukemia, which is in Phase III clinical trial in the United States and has approved in European Union; Crolibulin, a small molecule vascular disrupting agents (VDA) and apoptosis inducer that is in Phase II clinical trial for the treatment of patients with solid tumors; Azixa, a Phase II microtubular destabilizer that functions as a VDA; NanomAbs, a preclinical stage antibody-drug conjugate platform that allows the targeted delivery of combinations of chemotherapeutics into cancer cells; and bispecific antibodies, which are in preclinical stage against immune-oncology targets. In addition, it develops AmiKet, a prescription topical analgesic cream that has completed II clinical trials for the treatment of neuropathic pain; and LidoPAIN, an adhesive-backed, lidocaine-based patch that is in Phase II clinical trial for the treatment of acute lower back pain. Immune Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Englewood Cliffs, New Jersey.